Table 1.
Baseline characteristics of the subjects
| Characteristics | ARDS | ARDS-HSCT | Sepsis | Sepsis-HSCT | P (all groups) | P (ARDS vs ARDS-HSCT) |
|---|---|---|---|---|---|---|
| N | 6 | 5 | 7 | 5 | ||
| Age | 46 (37–60) | 39 (25–52) | 50 (26–59) | 55 (61–42) | 0.27 | 0.41 |
| WBC | 6.9 (3.1–16.8) | 11 (2.8–19.1) | 9 (4–42.1) | 8.6 (6.5–29.9) | 0.88 | 0.86 |
| % Neutrophils | 87 (71–98) | 95 (88–98) | 86 (63–95) | 80 (65–96) | 0.14 | 0.10 |
| % Lymphocytes | 6 (1–18) | 2 (0–10) | 10 (1–21) | 10 (1–21) | 0.26 | 0.12 |
| % Monocytes | 4 (1–15) | 2 (0–4) | 4 (1–11) | 9 (0–11) | 0.39 | 0.46 |
| Sepsis | 33.3% | 40.0% | 100% | 100% | 1 | |
| Vasopressors | 50% | 60% | 29% | 40% | 0.8 | 1 |
| Days since HSCT | 117 (50–490) | 148 (50–1322) | ||||
| APACHE II | 27.5 (21–47) | 30.0 (24–38) | 18 (14–40) | 19 (14–32) | 0.10 | 0.58 |
| ICU Mortality | 67% | 100% | 14% | 0% | 0.001 | 0.45 |
| Mechanical Ventilation | 100% | 100% | 29% | 40% | 0.04 | 1 |
| P/F ratio | 70.0 (41–205.0) | 81.3 (66.0–109.2) | 0.83 | |||
| Tidal volume (mL/kg) | 5.6 (5.2–7.6) | 6.5 (4.5–16.5) | 0.46 | |||
| Corticosteroids | 50% | 100.0% | 57% | 100% | 0.04 | 0.18 |
| Etanercept | 0.0% | 80.0% | 0% | 0% | 0.02 | |
| Other Immunosuppression | 50.0% | 80% | 0% | 60% | 0.02 | 0.5 |
| ARDS etiology | ||||||
| Pneumonia, influenza | 33% | 0% | ||||
| Pancreatitis | 17% | 0% | ||||
| Idiopathic pneumonia syndrome | 0% | 100% | ||||
| Idiopathic/CVD | 50% | 0% | ||||
| Infection | ||||||
| Type | ||||||
| Bacterial | 0% | 0% | 100% | 80% | ||
| Viral | 33% | 0% | 0% | 20% | ||
| Source | ||||||
| Blood | 0% | 0% | 43% | 60% | ||
| Lung | 33% | 0% | 14% | 20% | ||
| GI | 0% | 0% | 57% | 0% |
Idiopathic/collagen-vascular disease (CVD) diagnoses include acute interstitial pneumonia, cryptogenic organizing pneumonia, and collagen-vascular disease associated interstitial lung disease. Values given as median (range)